Final ID: Wed024
Ocaranza Maria Paz, Jimenez Veronica, Yanez Osvaldo, Jalil Jorge, Venegas Camilo, Candia Camila, Hermoso Marcela, Gabrielli Luigi, Morales Javier, Oyarzun Felipe, Torres Cristian, Lillo Pablo
37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensusNair Tiny, Jabbar P, Ray Saumitra, Hazra Prakash, Gupta Sushil, Joshi Ameya, Shaikh Shehla, B Jayagopal, Pandit Kaushik, Sharma D, Seshadri Krishna, S Sridhar